High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.

Khwaja J, Bomsztyk J, Mahmood S, Wisniowski B, Shah R, Tailor A, Yong K, Popat R, Rabin N, Kyriakou C, Sive J, Esposti SD, Larkin DFP, Worthington S, Hart A, Dowling E, Correia N, Bygrave C, Rydzewski A, Jamroziak K, Wechalekar AD

Open source

DOI: 10.1038/s41408-022-00717-2
Published: 2022 Sep 5
Container: Blood cancer journal
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41408-022-00717-2,
  title = {High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.},
  author = {Khwaja J and Bomsztyk J and Mahmood S and Wisniowski B and Shah R and Tailor A and Yong K and Popat R and Rabin N and Kyriakou C and Sive J and Esposti SD and Larkin DFP and Worthington S and Hart A and Dowling E and Correia N and Bygrave C and Rydzewski A and Jamroziak K and Wechalekar AD},
  year = {2022},
  journal = {Blood cancer journal},
  doi = {10.1038/s41408-022-00717-2},
  url = {https://doi.org/10.1038/s41408-022-00717-2}
}

RIS

TY  - JOUR
TI  - High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.
AU  - Khwaja J
AU  - Bomsztyk J
AU  - Mahmood S
AU  - Wisniowski B
AU  - Shah R
AU  - Tailor A
AU  - Yong K
AU  - Popat R
AU  - Rabin N
AU  - Kyriakou C
AU  - Sive J
AU  - Esposti SD
AU  - Larkin DFP
AU  - Worthington S
AU  - Hart A
AU  - Dowling E
AU  - Correia N
AU  - Bygrave C
AU  - Rydzewski A
AU  - Jamroziak K
AU  - Wechalekar AD
PY  - 2022
JO  - Blood cancer journal
DO  - 10.1038/s41408-022-00717-2
UR  - https://doi.org/10.1038/s41408-022-00717-2
ER  -

APA

J, K., J, B., S, M., B, W., R, S., A, T., K, Y., R, P., N, R., C, K., J, S., SD, E., DFP, L., S, W., A, H., E, D., N, C., C, B., A, R., K, J., & AD, W. (2022). High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.. Blood cancer journal. https://doi.org/10.1038/s41408-022-00717-2

Source records

pubmed · retrieved 2026-09-25T14:25:47.743Z